Author Interviews, Dermatology, Immunotherapy, NEJM, University of Pittsburgh / 06.10.2022
NEJM: Trial of IVIG for Autoimmune Disorder Dermatomyositis
MedicalResearch.com Interview with:
Rohit Aggarwal, MD, MS
Rheumatology, Professor of Medicine
Medical Director, Arthritis and Autoimmunity Center
Sub-Specialty Education Coordinator
Division of Rheumatology Department of Medicine
University of Pittsburgh
MedicalResearch.com: What is the background for this study?
Response: Dermatomyositis is a rare autoimmune inflammatory disease that affects muscles and skin, although muscular forms without skin symptoms and vice versa are also seen. The exact etiology of the disease is not known but is thought to be immune-mediated with many patients having highly specific autoantibodies. There is no cure for dermatomyositis, but several types of treatment have been successfully used in the last years including different kinds of immunosuppressants (e.g. steroids) and intravenous immune globulins (IVIG) to improve the patient’s condition. So far, none of these treatments was approved for use in dermatomyositis based on large, randomized, placebo-controlled trials. Their effectiveness was mainly deduced from clinical experience and from small clinical trials. The ProDERM study was the first large, pivotal, randomized placebo-controlled trial to evaluate the efficacy and safety of intravenous immune globulin (IVIG) in dermatomyositis patients.
(more…)